Saad Z. Usmani, MD, FACP

Articles

Dr Usmani on Approaching Treatment Decisions in High-Risk Multiple Myeloma

October 5th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses the complexity of approaching frontline treatment decisions in patients with high-risk multiple myeloma.

Dr Usmani on Unmet Needs in the Treatment of High-Risk Multiple Myeloma

September 22nd 2023

Saad Z. Usmani, MD, MBA, FACP, discusses unmet needs in patients with high-risk multiple myeloma being treated in the frontline setting, highlighting areas of potential further exploration within this landscape.

Dr Usmani on Identifying High-Risk Patients With Multiple Myeloma

September 15th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses methods for identifying patients with high-risk multiple myeloma and notable disease characteristics in this population.

Dr. Usmani on the Potential Future of Isatuximab in Multiple Myeloma

April 26th 2021

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.

Dr. Usmani on Optimizing Treatment Selection in Relapsed/Refractory Multiple Myeloma

April 16th 2021

Saad Z. Usmani, MD, FACP, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

Dr. Usmani on Situations that Indicate the Need for Immediate Treatment in R/R Multiple Myeloma

February 14th 2020

Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.

Dr. Usmani on Treatment Considerations in Relapsed/Refractory Multiple Myeloma

February 6th 2020

Saad Z. Usmani, MD, FACP, discusses treatment considerations in relapsed/refractory multiple myeloma.

Dr. Usmani on CAR T Cells, Bispecific Antibodies, and ADCs in Multiple Myeloma

October 31st 2019

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

Dr. Usmani on DREAMM Trials in Multiple Myeloma

October 9th 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the DREAMM-1 and DREAMM-2 trials in multiple myeloma.

Dr. Usmani on Impact of BCMA on the Myeloma Treatment Landscape

September 15th 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.

Dr. Usmani on Treatment of Newly Diagnosed Myeloma

April 18th 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the treatment of patients with newly diagnosed myeloma.

Dr. Usmani on Management of Early Relapse in Multiple Myeloma

March 13th 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the management of early relapse in multiple myeloma.

Dr. Usmani Discusses Management of Early Relapse in Myeloma

March 2nd 2019

Saad Z. Usmani, MD, FACP, shares his advice for the management of early relapse in patients with multiple myeloma.